In summary, these results demonstrate the potential anti-tumour effects of IgE antibody therapy against a range of tumour targets and suggest that IgE class antibodies have the capacity to activate FcεR-expressing effector cells to induce tumour cell killing in vivo. Here, IGHE is linked to neoplasm.